
Kerala switches to generic SMA drug Natsmart
The story in brief
In February 2026, the Keralam government approved Natsmart, a generic version of Risdiplam, to manage spinal muscular atrophy. The regulator stated bioequivalence studies are unnecessary, dismissing claims of efficacy concerns as baseless. Despite cost savings, some parents urge a return to the branded drug.